New combo shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT05171660
First seen Feb 17, 2026 · Last updated May 17, 2026 · Updated 14 times
Summary
This phase 3 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and a targeted therapy (bevacizumab) helps people with a specific type of advanced colorectal cancer (RAS-mutant, microsatellite stable) live longer without their cancer growing. The study includes 446 adults who have not had prior treatment for their metastatic disease. The goal is to see if the combination works better than the standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xuefeng Fang
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.